Trial Profile

Nab-P+Cb+PD1 Inhibitor Neoadjuvant Therapy for Early TNBC: a Single Center, Non Blinded, Randomized Phase II Clinical Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
Indications HER2 negative breast cancer; Triple negative breast cancer
Focus Therapeutic Use

Most Recent Events

05 Dec 2025 Protocol has been amended to remove 2 arms, (Experimental: 6*Chemotherapy drugs (Nab-P, d1, Cb, d1)+6*Immunosuppressants (d1)+5*anti-angiogenic drugs (d1 and Experimental: 6*Chemotherapy drugs (Nab-P, d1,8,15, Cb, d1)+6*Immunosuppressants (d1)+5*anti-angiogenic drugs (d1)) , it has changed from 4 to 2.
05 Dec 2025 Planned End Date changed from 6 Nov 2025 to 31 May 2026.
05 Dec 2025 Planned primary completion date changed from 6 Nov 2025 to 31 May 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com